Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

Combination of drugs produces dramatic tumor responses in advanced melanoma patients

  • Posted: June 3, 2013

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial from Memorial Sloan-Kettering Cancer Center simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Click here to read full press release.

###

NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.